Used in research and therapeutic development targeting inflammatory and autoimmune diseases, this antibody specifically binds to CCL5 (RANTES), a chemokine involved in recruiting immune cells to sites of inflammation. By neutralizing CCL5 activity, it helps modulate immune responses associated with conditions such as rheumatoid arthritis, multiple sclerosis, and atherosclerosis. It is also employed in studies related to HIV, as CCL5 can influence viral entry through interaction with CCR5 receptors. The antibody serves as a critical tool in validating CCL5 as a therapeutic target and in developing biologics for chronic inflammatory conditions.